Why Most Peptide Evidence Is Preclinical

The Preclinical Evidence Problem

The vast majority of peptides discussed in health and fitness communities have never been tested in human clinical trials. This is not because the peptides are uninteresting or because scientists are lazy. It is because the economics, regulatory structure, and patent landscape of modern drug development systematically exclude most peptides from the path to human testing.

Understanding why this gap exists is essential for anyone trying to make sense of peptide research. It changes how you interpret claims, how you assess risk, and how you calibrate expectations.

Who this page is for, and who it isn’t for

This page is for anyone who has wondered why promising peptides remain stuck at the animal study stage. It explains the structural forces that determine which compounds move toward human testing and which do not, regardless of their scientific merit. This page does not argue that preclinical-only peptides should be used or avoided. It provides context for informed decision-making.

The Cost of Clinical Trials

The single most important barrier to human clinical trials is cost. Moving a compound from preclinical research to FDA approval typically costs between $1 billion and $2.6 billion.

This figure includes the direct costs of conducting trials, the cost of regulatory compliance, the cost of failed compounds that didn’t make it, and the opportunity cost of capital tied up for years before any revenue is possible.

The breakdown is roughly:

• Phase I (safety, 20-80 participants): $2–10 million
• Phase II (preliminary efficacy, 100-300 participants): $10–50 million
• Phase III (confirmatory, 300-3,000+ participants): $50–300+ million
• Regulatory submission, manufacturing scale-up, post-market surveillance: Additional tens of millions

No pharmaceutical company, academic institution, or research foundation undertakes this expenditure without a clear path to financial return. This economic reality, not scientific merit, determines which compounds get tested in humans.

The Patent Problem

The ability to patent a compound and protect that patent for enough time to recoup investment is the fundamental driver of pharmaceutical development. For many peptides, patent protection is either impossible or commercially inadequate.

Why Some Peptides Can’t Be Effectively Patented

A compound that occurs naturally cannot generally be patented in its natural form. You can patent a specific use, a specific formulation, or a specific modification, but not the molecule itself.

BPC-157 is a fragment of a protein (Body Protection Compound) that occurs naturally in human gastric juice. The peptide sequence itself is not patentable as a novel composition of matter. A company could potentially patent a specific formulation, delivery system, or therapeutic indication, but these patents are narrower and easier to design around than a composition-of-matter patent.

This creates a financial dilemma: a company that spends $500 million proving BPC-157 works for tendon repair cannot prevent competitors from selling the same peptide for the same purpose, because the peptide sequence itself isn’t patented. The investment can’t be recouped through exclusive sales.

The Exceptions Prove the Rule

The peptides that have reached FDA approval are almost uniformly those with strong patent protection, typically through structural modification.

Semaglutide is not natural GLP-1. It is a heavily modified analog: a fatty acid is attached at position 26, an amino acid is substituted at position 8, and the molecule is engineered for dramatically extended half-life (about one week vs. two minutes for natural GLP-1). These modifications are patentable. Novo Nordisk’s composition-of-matter patent on semaglutide enabled the billion-dollar investment required for clinical development.

Tirzepatide is similarly a novel, patentable molecule, a dual GIP/GLP-1 receptor agonist that doesn’t exist in nature. Eli Lilly holds strong patents.

Tesamorelin is a modified form of GHRH with proprietary modifications. Theratechnologies holds the patents.

Bremelanotide (PT-141) is a synthetic cyclic peptide with a patented structure.

The pattern is clear: pharmaceutical companies invest in peptides they can own exclusively. Naturally derived peptide sequences, regardless of how promising their preclinical data, rarely attract the investment needed for clinical trials.

The “Valley of Death”

In drug development, the “valley of death” refers to the gap between basic scientific discovery and commercial development. For peptides, this valley is especially wide.

Academic researchers may discover that a peptide has impressive effects in animal models. They publish their findings. But the academic research system is not designed to fund the hundreds of millions needed for clinical trials. That requires industry partnership.

And industry partnership requires patent protection. Without it, the research stays on the shelf: promising, published, and unused.

Regulatory Complexity

Even when funding and patents are not obstacles, the regulatory pathway itself is a barrier.

The FDA Approval Process

The FDA requires evidence of safety and efficacy from well-designed clinical trials. The standards are high: randomized, double-blinded, placebo-controlled trials with adequate sample sizes, pre-registered endpoints, and rigorous statistical analysis.

These standards exist for good reason. They protect patients from ineffective or harmful treatments. But they also create a threshold that most peptides will never clear, simply because no one will fund the required studies.

Compounding Pharmacy Pathway

Compounding pharmacies historically provided a partial workaround. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare medications based on individual prescriptions or in bulk, using approved or not-yet-approved ingredients listed on the FDA’s bulk drug substance list.

Some peptides (including, at various times, BPC-157, AOD-9604, and others) have been available through compounding pharmacies. However, the FDA has increasingly restricted this pathway, placing certain peptides on its “difficult to compound” list or declining to add them to approved bulk substance lists.

This regulatory tightening reflects the FDA’s position that peptides used in compounding should meet the same evidentiary standards as approved drugs. Whether this position appropriately balances patient access against safety concerns is a matter of ongoing debate.

International Regulatory Variation

Different countries have different regulatory frameworks. Selank and Semax are approved in Russia based on Russian clinical data and regulatory standards. This data does not satisfy FDA requirements. The result is a compound that is simultaneously “approved” and “unproven,” depending on which regulatory authority you reference.

This creates genuine confusion for consumers and researchers. The existence of Russian approval is not equivalent to FDA approval. The clinical trial standards, reporting requirements, and oversight mechanisms differ. But dismissing all non-FDA research as worthless is also inappropriate.

What Preclinical Evidence Can and Cannot Tell Us

Given that most peptides will likely remain at the preclinical stage for the foreseeable future, understanding what preclinical evidence actually means is critical.

What Preclinical Evidence Can Tell Us

Biological activity exists. If a peptide accelerates tendon healing in rats, it has genuine biological activity. The molecule does something in a living organism. This is meaningful; it eliminates the possibility that the compound is biologically inert.

A mechanism is plausible. Preclinical studies that identify receptor binding, signaling pathway activation, and downstream effects provide a mechanistic narrative. When the mechanism is coherent and consistent across multiple studies, it increases confidence that the effect is real (at least in the model studied).

Basic safety is established. Preclinical toxicology studies can identify gross toxicity, organ damage, and lethal doses. A peptide that is well-tolerated in animals at a wide range of doses is less likely to cause acute harm in humans, though this is not a guarantee.

Dose-response relationships are characterized. Animal studies establish effective dose ranges and dose-response curves, which provide starting points for hypothetical human dosing (through allometric scaling).

What Preclinical Evidence Cannot Tell Us

Whether it works in humans. Approximately 90% of drugs that succeed in preclinical testing fail in human clinical trials. This failure rate reflects fundamental biological differences between species that cannot be predicted from animal data alone.

The correct human dose. Allometric scaling (adjusting for body weight and metabolic rate) provides estimates, but effective human doses can differ substantially from scaled animal doses.

The human side effect profile. Species-specific differences in receptor expression, organ sensitivity, and drug metabolism mean that side effects in humans may differ qualitatively from those in animals.

Long-term safety. Most animal studies are weeks to months in duration. Long-term effects in humans (years, decades) cannot be extrapolated from short-term animal data.

Drug interactions. Animal studies rarely test interactions with the medications humans commonly take. For more on this topic, see how peptides are studied.

How to Calibrate Expectations

Given this landscape, a realistic framework for evaluating peptide evidence involves acknowledging several tiers of confidence:

High confidence: FDA-approved peptides with Phase III data (semaglutide, tirzepatide, tesamorelin, PT-141). These have demonstrated efficacy and characterized safety in thousands of humans. Uncertainty remains (long-term effects, rare adverse events), but the evidence base is strong.

Moderate confidence: Peptides with some human data, such as limited Phase I/II trials or clinical approval in non-Western regulatory environments (e.g., Selank, Semax in Russia). These have evidence of human safety and preliminary efficacy, but the data is less robust than Phase III evidence.

Low confidence, interesting signal: Peptides with extensive, consistent preclinical evidence but no human trials (BPC-157, TB-500, ipamorelin). The preclinical data is genuine and sometimes impressive, but the translation to humans is unverified. Community use provides anecdotal evidence but cannot substitute for controlled trials.

Speculative: Peptides with limited preclinical data, single studies, or evidence only from in vitro work. The evidence base is too thin for meaningful evaluation.

This framework doesn’t tell you what to do. It tells you what you know, and, more importantly, what you don’t know, about any given peptide. For practical tools on applying this framework, see how to read peptide claims critically.

Will This Change?

Several developments could shift the preclinical evidence landscape for peptides:

New funding models. Non-profit organizations, patient advocacy groups, and government funding agencies could sponsor clinical trials for non-patentable compounds. Some efforts along these lines exist but remain small relative to the need.

Platform trial designs. Adaptive platform trials that test multiple compounds simultaneously could reduce per-compound costs.

Regulatory reform. Changes to FDA pathway requirements, expanded access programs, or recognition of non-US clinical data could lower barriers.

Commercial interest. If a company finds a way to create proprietary formulations, delivery systems, or indications for otherwise generic peptides, commercial interest could drive clinical testing.

Academic initiatives. University-based clinical trials, while typically smaller than industry trials, could provide initial human data that attracts further investment.

However, it is realistic to expect that many popular research peptides will lack human clinical trial data for years to come. The structural barriers are deep and the financial incentives are misaligned. Understanding this reality is part of understanding the peptide landscape honestly.

Frequently Asked Questions

If a peptide works in rats, what are the chances it works in humans?

Historically, about 10% of compounds that succeed in preclinical testing also succeed in human clinical trials. However, this figure covers all pharmaceutical development, not peptides specifically. Some compounds fail due to toxicity rather than inefficacy. And compounds with particularly strong and consistent preclinical data may have higher translation rates, though this has not been quantified for peptides specifically. This is one of the most common misconceptions about peptides — assuming that animal results predict human outcomes.

Why can’t universities run clinical trials for these peptides?

They can, and occasionally do, but university clinical trials are typically small, funded by grants, and limited in scope. A Phase III trial large enough for FDA approval requires resources beyond most academic budgets. Some university-initiated Phase I/II trials have been conducted for peptides, and these provide valuable data even when they don’t lead to approval.

If semaglutide got approved, why can’t other peptides?

Semaglutide got approved because Novo Nordisk could patent it (due to novel structural modifications), invest over a billion dollars in clinical trials, and project commercial returns sufficient to justify the investment. Most research peptides lack one or more of these elements, typically patent protection.

Isn’t it unethical to withhold potentially beneficial treatments because of economics?

This is a legitimate ethical debate. The current system prioritizes rigorous evidence of safety and efficacy, which protects patients from unproven treatments. But it also means that compounds without commercial viability, regardless of scientific promise, may never be properly tested. There is no easy resolution to this tension.

Can I access clinical trial data for peptides?

ClinicalTrials.gov lists registered clinical trials, including those for peptides. PubMed indexes published results. For peptides with FDA approval, FDA review documents are publicly available and contain detailed efficacy and safety data.

References

1. DiMasi JA, Grabowski HG, Hansen RW. “Innovation in the pharmaceutical industry: New estimates of R&D costs.” J Health Econ. 2016;47:20-33. PubMed
2. Dowden H, Munro J. “Trends in clinical success rates and therapeutic focus.” Nat Rev Drug Discov. 2019;18(7):495-496. PubMed
3. Hay M, et al. “Clinical development success rates for investigational drugs.” Nat Biotechnol. 2014;32(1):40-51. PubMed
4. Muttenthaler M, et al. “Trends in peptide drug discovery.” Nat Rev Drug Discov. 2021;20(4):309-325. PubMed
5. Butler D. “Translational research: crossing the valley of death.” Nature. 2008;453(7197):840-842. PubMed
6. US Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A and 503B.” FDA.gov. [research needed — URL changes]

Related Articles

Peptide

BPC-157: What the Research Actually Shows About This Healing Peptide

An evidence-first review of BPC-157 research — preclinical findings on tissue repair, gut protection, and wound healing, with honest assessment of what is and isn't proven.

Peptide

Semaglutide: What the Clinical Evidence Shows About This GLP-1 Agonist

A comprehensive, evidence-first review of semaglutide (Ozempic/Wegovy) — clinical trial data on weight loss and cardiovascular outcomes, mechanism of action, side effects, and practical considerations.

Peptide

Tirzepatide: What the Clinical Evidence Shows About This Dual Incretin Agonist

An evidence-based review of tirzepatide (Mounjaro/Zepbound), covering clinical trial data on weight loss, diabetes, cardiovascular outcomes, and safety.